ストックスクリーナーアプリを入手
630.27
0.91%
6.73
前日終値:
$623.54
開ける：
$629.9
24時間の取引高:
225.46K
Relative Volume:
0.24
時価総額：
$66.05B
収益：
$14.92B
当期純損益:
$4.42B
株価収益率:
15.36
EPS:
41.0422
ネットキャッシュフロー:
$3.79B
1週間 パフォーマンス:
+0.92%
1か月 パフォーマンス:
+4.75%
6か月 パフォーマンス:
-18.48%
1年 パフォーマンス:
+17.63%
1日の値動き範囲:
$623.89
$632.85
1週間の範囲:
$619.70
$638.76
52週間の値動き範囲:
$529.69
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
630.02 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
499.45 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
906.41 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.19 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.19 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-31 | 再開されました | Piper Sandler | Overweight |
| 2026-03-06 | 開始されました | Barclays | Overweight |
| 2026-01-07 | アップグレード | BofA Securities | Underperform → Buy |
| 2025-12-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 開始されました | HSBC Securities | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-14 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-30 | ダウングレード | Argus | Buy → Hold |
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Regeneron Pharma strengthens its position in biotech. Focus on long-term growth and innovation - AD HOC NEWS
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program - BioSpace
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme - Pharmaceutical Technology
Element Squared LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA selects seven companies including Eli Lilly and Regeneron for accelerated manufacturing review pilot - grafa.com
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Benzinga
Regeneron opens the week with analyst focus, shares on NASDAQ radar - AD HOC NEWS
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds? - Insider Monkey
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why - Insider Monkey
How the president of Regeneron pursued his American dream - New York Post
Regeneron clears key moving averages, shares trade below consensus targets - Ad-hoc-news.de
Pictet Asset Management Holding SA Sells 30,616 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The EYLEA injection from Regeneron Pharmaceuticals Inc.high-dose eye therapy pushes into diabetic - Ad-hoc-news.de
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment - simplywall.st
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron myasthenia gravis therapy undergoes US and EU review - MSN
why dominant pharmaceutical firms are paying billion dollar premiums for immunology assets - grafa.com
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Biotech's Rapid Response to the 2026 Ebola Outbreak: Vaccines, Antibodies, and Therapeutics Advance - Investorideas.com
Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), AbSci (ABSI) and Viking Therapeutics (VKTX) - The Globe and Mail
Aethlon Medical tracks Ebola outbreak, readies Hemopurifier talks - Stock Titan
Louisiana State Employees Retirement System Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron highlights robust pipeline progress, shares trade in a neutral technical range - Ad-hoc-news.de
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – GETTEX:RGO - TradingView
Price to earnings forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
The EYLEA Injection from Regeneron Pharmahigh-dose eye therapy targets chronic retinal disease - Ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:REGN) - TradingView
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast - The Manila Times
Regeneron schedules July 30 earnings call and webcast - Stock Titan
REGNUS Forecast — Price Target — Prediction for 2027 - TradingView
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $788 - Moomoo
Assenagon Asset Management S.A. Has $160.54 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prominent construction companies get a portion of Regeneron's $2B Saratoga expansion - The Business Journals
Will Priority-Reviewed Quarterly siRNA gMG Therapy Change Regeneron Pharmaceuticals' (REGN) Narrative? - Yahoo Finance
(REGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
BI Asset Management Fondsmaeglerselskab A S Sells 2,968 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc (REGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Regeneron Pharmaceuticals (REGN) Leans On Pipeline Promise As Undervaluation Case Stays In Focus - simplywall.st
Regeneron (REGN) Advances Cemdisiran for Myasthenia Gravis with Regulatory Approvals - GuruFocus
Regeneron gets US, EU review for myasthenia gravis drug (REGN) - Seeking Alpha
Regeneron's Applications for gMG Drug Accepted by FDA and EMA - Yahoo Finance
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Regeneron (REGN) and Alkermes (ALKS) - The Globe and Mail
Regeneron highlights RNAi drug submissions, shares trade in Nasdaq range - AD HOC NEWS
Emerging Stars in Weight Loss: Regeneron and Amgen - Intellectia AI
2 Underrated Weight Loss Stocks to Buy and Hold - The Motley Fool
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
0.22%
3.75%
大文字化:
|
ボリューム (24 時間):